Zimmerman Justin, Giuliano Christopher, Kale-Pradhan Pramodini B
Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Science, Wayne State University, Detroit, MI, USA.
Henry Ford St. John Hospital, Detroit, MI, USA.
Ann Pharmacother. 2025 Jul;59(7):657-665. doi: 10.1177/10600280241293773. Epub 2024 Dec 7.
The objective was to review the pharmacology, efficacy, and safety of intravenous ceftobiprole in the treatment of bloodstream infections, acute bacterial skin and skin structure infections (ABSSSIs), community-acquired pneumonia (CAP), and hospital-acquired pneumonia (HAP), or ventilator-associated pneumonia (VAP).
PubMed and ClinicalTrials.gov were searched using the following terms: ceftobiprole, ceftobiprole medocaril, ceftobiprole medocaril sodium, Zevtera, and BAL5788.
Articles published in English between January 1985 and August 15, 2024, related to pharmacology, safety, efficacy, and clinical trials were reviewed.
Ceftobiprole has shown similar efficacy to comparator antibiotics in CAP, ABSSSIs, and bloodstream infections. Overall treatment success in patients with bacteremia was 69.8% and 68.7%; 91.3% and 88.1% with ABSSSIs and 86.6% and 87.4% with CAP in ceftobiprole and comparator groups, respectively. Finally, in the management of HAP and VAP, ceftobiprole was inferior in the VAP population. Ceftobiprole had a favorable safety profile with gastrointestinal adverse effects occurring more frequently than comparators.Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs:Clinicians have limited options to treat multidrug-resistant infections. Ceftobiprole has demonstrated efficacy against causative pathogens in specific infections including methicillin-resistant bacteremia (SAB), ABSSSI, and CAP and may be considered a viable alternative. However, ceftobiprole's impact on HAP, VAP, and febrile neutropenia needs to be further delineated.
Ceftobiprole's broad-spectrum activity makes it a viable option for treating patients hospitalized with CAP, ABSSSI, and SAB. Further studies are needed in severely ill HAP or VAP, febrile neutropenia, and pediatric patients.
本研究旨在综述静脉注射头孢比普对血流感染、急性细菌性皮肤及皮肤结构感染（ABSSSI）、社区获得性肺炎（CAP）、医院获得性肺炎（HAP）或呼吸机相关性肺炎（VAP）的药理学、疗效及安全性。
使用以下检索词在PubMed和ClinicalTrials.gov数据库进行检索：头孢比普、头孢比普甲磺酸盐、头孢比普甲磺酸钠、泽韦特拉（Zevtera）和BAL5788。
对1985年1月至2024年8月15日期间发表的英文文章进行综述，这些文章涉及药理学、安全性、疗效及临床试验。
在CAP、ABSSSI和血流感染方面，头孢比普已显示出与对照抗生素相似的疗效。在菌血症患者中，头孢比普组和对照组的总体治疗成功率分别为69.8%和68.7%；ABSSSI患者分别为91.3%和88.1%；CAP患者分别为86.6%和87.4%。最后，在HAP和VAP的治疗中，头孢比普在VAP患者群体中疗效较差。头孢比普具有良好的安全性，胃肠道不良反应的发生频率高于对照药物。与现有药物相比对患者护理和临床实践的相关性：临床医生治疗多重耐药感染的选择有限。头孢比普已证明对包括耐甲氧西林菌血症（SAB）、ABSSSI和CAP在内的特定感染的致病病原体有效，可被视为一种可行的替代药物。然而，头孢比普对HAP、VAP和发热性中性粒细胞减少症的影响需要进一步明确。
头孢比普的广谱活性使其成为治疗因CAP、ABSSSI和SAB住院患者的可行选择。对于重症HAP或VAP、发热性中性粒细胞减少症患者及儿科患者，还需要进一步研究。
